If you purchase an independently reviewed product or service through a link on our website, Variety may receive an affiliate commission. Although he calls himself an “Image Architect,” titles don’t ...
I am selling my remaining shares in TARS for 90% gain. I am adding to my position in DERM on the dip back to $7. I am initiating a new position in REPL with 5% portfolio weighting. REPL- FDA's ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback